n-[[2-methyl-4-hydroxycarbamoyl]but-4-yl-n]-benzyl-p-[phenyl]-p-[methyl]phosphinamid

N-[[2-methyl-4-hydroxycarbamoyl]but-4-yl-n]-benzyl-p-[phenyl]-p-[methyl]phosphinamid is an experimental small molecule inhibitor, structurally related to phosphinamide compounds. It has been studied as a hydrolase inhibitor, specifically targeting stromelysin‑1 (matrix metalloproteinase 3, MMP‑3), which is involved in the breakdown of extracellular matrix components and implicated in diseases such as osteoarthritis. The compound was deposited for structure-based drug design studies and protein crystal structure analysis but has not advanced to clinical development or approval[1][2].

Other names

DB08507DB-08507DB 08507